Last year, United Therapeutics Corp generated 1.29B USD for its biggest-performing segment, Tyvaso DPI. The United States made the largest contribution, accounting for 3.04B USD last year. For the latest quarter, United Therapeutics Corp reported the revenue of 326.60M USD for the period ending 2026-06-30, which came from the top-performing segment, Tyvaso DPI. United States contributed the highest revenue, at 783.30M USD.